Table 3.
Association between nailfold videocapillaroscopy patterns and disease characteristics of patients with systemic sclerosis included in the discovery cohort
| NVC pattern | P value | Multiple linear regression (r) |
P value | ||
|---|---|---|---|---|---|
| Early/active (n = 36) |
Late (n = 24) |
||||
| Age, median (range) | 58 | 53 | 0.2 | ||
| Females, n (%) | 27 (75) | 19 | 0.9 | ||
| Disease duration, median (range) | 9.91 | 7.20 | 0.2 | ||
| Diffuse cutaneous subset, n (%) | 13 (36) | 11 (46) | 0.9 | ||
| Modified Rodnan skin score > 14, n (%) | 6 (17) | 13 (54) | 0.005* | 0.42 | 0.0008 |
| History of digital ulcers, n (%) | 13 (36) | 16 (67) | 0.03* | 0.25 | 0.03 |
| Pulmonary fibrosis, n (%) | 15 (42) | 13 (54) | 0.5 | ||
| Pulmonary arterial hypertension on RHC, n (%) | 2 (6) | 2 (8) | 0.9 | ||
| Positive antitopoisomerase antibodies, n (%) | 12 (33) | 16 (67) | 0.02* | ||
| Positive anticentromere antibodies, n (%) | 9 (25) | 3 (13) | 0.4 | ||
| FVC < 75, n (%) | 5 (14) | 8 (33) | 0.1* | 0.29 | 0.01 |
| DLCO/VA < 75%, n (%) | 9 (25) | 14 (58) | 0.02* | ||
| Treatment with angiotensin-converting enzyme inhibitors, n (%) | 8 (22) | 11 (46) | 0.09* | ||
| Treatment with endothelin-receptor antagonists and/or PDE5 inhibitors, n (%) | 4 (11) | 8 (33) | 0.08* | ||
DLCO/AV, diffusing capacity for carbon monoxide/alveolar volume; FVC, forced vital capacity; NVC, nailfold videocapillaroscopy; PDE5, phosphodiesterase type 5; RHC, right heart catheterization.
* Variables included in multiple regression analysis